Ford Motor Company vs Novartis AG — how do they compare? Ford Motor Company trades at $13.98 (market cap $55.83B), while Novartis AG trades at $154.71 (market cap $298.18B). The key difference: Novartis AG is far larger — about 5.3× Ford Motor Company's market cap, and Ford Motor Company pays the higher dividend (4.29%). Which is the better fit depends on your goals.
| F | NVS | |
|---|---|---|
Market Cap | $55.83B | $298.18B |
Sector | Consumer Cyclical | Health |
52-Week High | $17.44 | $168.62 |
52-Week Low | $11.14 | $118.55 |
Enterprise Value | $187.79B | $339.50B |
Dividend Yield | 4.29% | 3.02% |
Signals from Pluang's Aura AI — not financial advice
Ford (F) trades at $13.98, up 1.38% with a bullish technical signal despite mixed fundamentals. The company reported negative net income of -$8.18B in 2025 but maintains strong operating cash flow of $21.28B. Recent news highlights Ford's new $28,350 Fathom EV truck launch for 2027, targeting affordable electric vehicles while managing EV transition costs through its profitable commercial Pro segment.
Outlook remains cautious with analyst consensus at $16.00 (43% buy ratings). Key opportunities include EV expansion and dividend stability ($0.15 quarterly), while risks involve persistent net losses, high debt levels (56.49% debt-to-asset), and competitive EV market pressures. The stock offers value with low P/E (11.84) but requires monitoring of profitability turnaround.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Trailing returns across standard periods
Latest headlines on both assets
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →